Summary
2018 was a memorable year for the bioscience sector, as the bear market created many bargain opportunities.
2019 is likely to produce more bargain stocks for the opportunistic and long-term oriented investors.
We drilled down on an extensive list to feature Regenxbio as our top pick for 2019 and beyond.
Our selection process is based on our M4 criteria that include medicine, market, money, and management.
Happy belated New Year to all!
Looking for more? I update all of my investing ideas and strategies to members of Integrated BioSci Investing. Start your free trial today ยป
The wise investor can profit if he can think independently of the crowd and reach the rich answer when the majority of financial opinion is leaning the other way. - The Father of Growth Investing (Philip Fisher)
